

DuPont Fluoroproducts
1007 Market Street
Wilmington, DE 19898



DuPont Fluoroproducts

February 21, 1995

Dr. Lance L. Simpson
Jefferson Clinical Center In Environ. Medicine
Room 314-Jah, Jefferson Medical College
1020 Locust St.
Philadelphia, PA 19107

Dear Dr. Simpson:

As we discussed over the telephone recently, we are interested in establishing a corporate policy on medical surveillance for our employees, particularly for the blood monitoring of telomeric acid fluorides, including perfluorooctanoic acid (C8). We are concerned about the potential long-term human health effects of these materials considering they all appear to have long biological half-lives. Your expertise is necessary to assist us in the design, conduct and interpretation of a monitoring program. Specifically, we are interested in a blood monitoring program design which includes relevant test batteries. The outcome of this program would be to ensure that our industrial hygiene programs are adequate to protect our employees from any potential adverse effects.

In addition to the above, we would also like you to suggest certain studies that we could conduct that would allow us to utilize our large toxicological database in developing a human risk model. We would like to discuss this program in greater depth with you, outlining in some detail the existing toxicity data that we have collected, and define more completely our issues on this bleeding monitoring program.

Please contact me at your earliest convenience in order that we can facilitate this program. Thank you for your consideration.

Sincerely,

William J. Brock, Ph.D.
Toxicology Consultant

WJB/jat

bcc: J. Walrath ✓

EID098719

JW000048

